Pharma Fridays – August 8, 2025

August 8, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Positive Phase 3 Trial Results for Lilly’s Oral Weight-Loss Drug, Orforglipron On August 7, Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Pharma Fridays

←Society Offers CEU and EBR for Clinicians this Fall, While Planning Meetings for Researchers in Coming Year

Animal Magnetism: Q&A With Erik Nelson, PhD→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today